JP2022507020A5 - - Google Patents

Info

Publication number
JP2022507020A5
JP2022507020A5 JP2021523948A JP2021523948A JP2022507020A5 JP 2022507020 A5 JP2022507020 A5 JP 2022507020A5 JP 2021523948 A JP2021523948 A JP 2021523948A JP 2021523948 A JP2021523948 A JP 2021523948A JP 2022507020 A5 JP2022507020 A5 JP 2022507020A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
pharmaceutically acceptable
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021523948A
Other languages
English (en)
Japanese (ja)
Other versions
JP7482861B2 (ja
JP2022507020A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/060350 external-priority patent/WO2020097389A1/en
Publication of JP2022507020A publication Critical patent/JP2022507020A/ja
Publication of JP2022507020A5 publication Critical patent/JP2022507020A5/ja
Application granted granted Critical
Publication of JP7482861B2 publication Critical patent/JP7482861B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021523948A 2018-11-09 2019-11-07 二環式化合物 Active JP7482861B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862758364P 2018-11-09 2018-11-09
US62/758,364 2018-11-09
US201962916739P 2019-10-17 2019-10-17
US62/916,739 2019-10-17
PCT/US2019/060350 WO2020097389A1 (en) 2018-11-09 2019-11-07 Bicyclic compounds

Publications (3)

Publication Number Publication Date
JP2022507020A JP2022507020A (ja) 2022-01-18
JP2022507020A5 true JP2022507020A5 (cg-RX-API-DMAC7.html) 2022-11-07
JP7482861B2 JP7482861B2 (ja) 2024-05-14

Family

ID=70611193

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523948A Active JP7482861B2 (ja) 2018-11-09 2019-11-07 二環式化合物

Country Status (11)

Country Link
US (1) US11866431B2 (cg-RX-API-DMAC7.html)
EP (1) EP3877356A4 (cg-RX-API-DMAC7.html)
JP (1) JP7482861B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210108367A (cg-RX-API-DMAC7.html)
CN (1) CN113302175A (cg-RX-API-DMAC7.html)
AU (1) AU2019375983A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021008741A2 (cg-RX-API-DMAC7.html)
CA (1) CA3118752A1 (cg-RX-API-DMAC7.html)
IL (1) IL282984A (cg-RX-API-DMAC7.html)
MX (1) MX2021005314A (cg-RX-API-DMAC7.html)
WO (1) WO2020097389A1 (cg-RX-API-DMAC7.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3877356A4 (en) 2018-11-09 2022-06-22 Vivace Therapeutics, Inc. BICYCLIC LINKS
WO2020160151A1 (en) * 2019-01-31 2020-08-06 Kyorin Pharmaceutical Co., Ltd. 15-pgdh inhibitors
AU2020257207B2 (en) 2019-04-16 2026-06-04 Vivace Therapeutics, Inc. Bicyclic compounds
WO2021224291A1 (en) * 2020-05-08 2021-11-11 Merck Patent Gmbh Tricyclic heterocycles useful as tead binders
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
AR123656A1 (es) 2020-09-30 2022-12-28 Univ Leuven Kath Derivados de 1,2,3,4-tetrahidroquinolina
WO2022120355A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof
BR112023014751A2 (pt) 2021-01-25 2023-10-03 Ikena Oncology Inc Combinação de um inibidor de tead de 3-(imidazol-4-il)-4-(amino)-benzenossulfonamida com um inibidor de egfr e/ou inibidor de mek para uso no tratamento de câncer de pulmão
WO2022233442A1 (en) * 2021-02-10 2022-11-10 Merck Patent Gmbh 2,8-dihydropyrazolo[3,4-b]indole derivatives for use in the treatment of cancer
CN117157278A (zh) * 2021-03-23 2023-12-01 柏奥艾奇实验室公司 Nlrp3炎性体的抑制剂
AU2022241754A1 (en) 2021-03-23 2023-10-19 BioAge Labs, Inc. Inhibitors of nlrp3 inflammasome
US12655150B2 (en) 2021-03-26 2026-06-16 Cedilla Therapeutics, Inc. TEAD inhibitors and uses thereof
AU2022258968A1 (en) 2021-04-16 2023-10-19 Ikena Oncology, Inc. Mek inhibitors and uses thereof
AU2021444255A1 (en) * 2021-05-05 2023-12-21 Cancer Research Technology Ltd. 2,8-dihydropyrazolo[3,4-b]indole derivatives for use in the treatment of cancer
CN117956996A (zh) * 2021-05-11 2024-04-30 Opna 生物公司 用于yap/tead调节的化合物和方法及其适应证
AR125921A1 (es) * 2021-05-19 2023-08-23 Genentech Inc Terapia de combinación
WO2022272036A1 (en) * 2021-06-25 2022-12-29 Cedilla Therapeutics, Inc. Tead inhibitors and uses thereof
EP4385978A4 (en) * 2021-08-12 2025-08-13 Tyk Medicines Inc POLYCYCLIC COMPOUND AND ITS USE
US20240374571A1 (en) 2021-09-01 2024-11-14 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
WO2023057371A1 (en) 2021-10-04 2023-04-13 Basilea Pharmaceutica International Ag, Allschwil 1,2,4-oxadiazol-5-one derivatives for the treatment of cancer
WO2023060227A1 (en) 2021-10-07 2023-04-13 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CN113861061A (zh) * 2021-10-25 2021-12-31 成都市科隆化学品有限公司 一种不含无机铵盐的氨基酸酰胺盐酸盐及其合成方法
US12030866B2 (en) 2021-12-23 2024-07-09 Springworks Therapeutics, Inc. 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD
CN114181039A (zh) * 2021-12-23 2022-03-15 凯美克(上海)医药科技有限公司 一种4,4-二苯基-3-丁烯-1-醇的合成方法
EP4469460A1 (en) 2022-01-28 2024-12-04 Bioage Labs, Inc. N-oxide inhibitors of nlrp3 inflammasome
WO2023150619A2 (en) 2022-02-02 2023-08-10 The Katholieke Universiteit Leuven Tetrahydropyridopyrimidines and related analogs for inhibiting yap/taz-tead
AU2023225036A1 (en) * 2022-02-25 2024-07-11 Katholieke Universiteit Leuven Dihydroquinazolinones and related analogs for inhibiting yap/taz-tead
CN114539080A (zh) * 2022-03-02 2022-05-27 八叶草健康产业研究院(厦门)有限公司 一种2-(2-氨基-6-氯苯基)-乙酸钠的制备方法
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
JP2025513725A (ja) * 2022-03-22 2025-04-30 スポロス バイオディスカバリー,インク. Tead阻害剤および使用方法
CN119768393A (zh) 2022-05-25 2025-04-04 医肯纳肿瘤学公司 Mek抑制剂和其用途
TW202409001A (zh) 2022-07-06 2024-03-01 美商維維迪昂醫療公司 包含wrn解旋酶抑制劑之醫藥組成物
CN119968359A (zh) 2022-09-29 2025-05-09 英矽智能科技知识产权有限公司 Tead抑制剂及其使用方法
WO2024092116A1 (en) 2022-10-26 2024-05-02 Ikena Oncology, Inc. Combination of tead inhibitors and egfr inhibitors and uses thereof
WO2024105610A1 (en) 2022-11-18 2024-05-23 Novartis Ag Pharmaceutical combinations and uses thereof
WO2024173761A1 (en) 2023-02-17 2024-08-22 Ikena Oncology, Inc. Combinations comprising mek inhibitors for use in the treatment of cancer
CN120659608A (zh) 2023-02-23 2025-09-16 诺华股份有限公司 用于治疗癌症的tead抑制剂和kras g12d抑制剂组合
EP4669319A1 (en) 2023-02-23 2025-12-31 Novartis AG TEAD AND HER2 INHIBITOR COMBINATIONS FOR CANCER TREATMENT
JP2026519523A (ja) * 2023-05-24 2026-06-16 ビアクティカ セラピューティクス エービー Teadへの結合剤としての芳香族アミドおよびそのコンジュゲート
WO2025054190A1 (en) * 2023-09-05 2025-03-13 Vivace Therapeutics, Inc. Pharmaceutical formulations and dosing schedules of a yap/taz-tead inhibitor
CN117327007B (zh) * 2023-09-26 2024-09-13 上海陶术生物科技有限公司 一种vt107的制备方法
WO2025101655A1 (en) * 2023-11-08 2025-05-15 Vivace Therapeutics, Inc. Compounds for modulating yap-tead/hippo pathway
WO2025141118A1 (en) 2023-12-27 2025-07-03 Institut National de la Santé et de la Recherche Médicale Arylalkyloxyindole compounds and derivatives and their use
WO2025207644A1 (en) 2024-03-26 2025-10-02 BioAge Labs, Inc. Inhibitors of nlrp3 inflammasome
TW202547484A (zh) 2024-04-10 2025-12-16 瑞士商諾華公司 藥物組合及其用途

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
JP2001511813A (ja) * 1997-02-18 2001-08-14 ニューロクライン バイオサイエンシーズ,インコーポレイテッド Crfレセプターアンタゴニストおよびそれらに関連する方法
EP1042295B1 (en) 1997-12-22 2005-09-07 Pharmacia & Upjohn Company LLC 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
IT1303123B1 (it) 1998-10-13 2000-10-30 Rotta Research Lab Derivati basici di benz(e)isoindol-1-oni e pirrolo(3,4-c)chinolin-1-oni ad attivita' 5ht3 antagonista, loro preparazione ed
HK1045306A1 (zh) 1999-06-03 2002-11-22 Abbott Laboratories 抑制细胞黏附的抗炎化合物
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
US7067532B2 (en) 2000-11-02 2006-06-27 Astrazeneca Substituted quinolines as antitumor agents
FR2827599A1 (fr) * 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
US7544699B2 (en) 2003-08-08 2009-06-09 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
JP4847459B2 (ja) 2005-01-25 2011-12-28 田辺三菱製薬株式会社 ノルバリン誘導体及びその製造方法
CN102351791B (zh) 2006-01-27 2014-10-29 菲布罗根有限公司 使低氧诱导因子(hif)稳定的氰基异喹啉化合物
US20070259960A1 (en) 2006-02-16 2007-11-08 Fibrogen, Inc. Compounds and methods for treatment of stroke
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
WO2008023157A1 (en) 2006-08-21 2008-02-28 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as m3-receptor modulators
AR065093A1 (es) * 2007-02-05 2009-05-13 Merck Frosst Canada Ltd Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos
EP2481735A1 (en) 2007-05-09 2012-08-01 Pfizer Inc. Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials
ES2614269T3 (es) * 2007-08-03 2017-05-30 Biotron Limited Procedimientos y composiciones antivíricas frente a la hepatitis C
BRPI0819453A2 (pt) 2007-11-28 2014-10-07 Dana Farber Cancer Inst Inc Composto, métodos para tratar um distúrbio relacionado com atividade de cinase, para tratar câncer em um paciente, para inibir a atividade de cinase e para identificar um composto que modula a atividade de cinase de bcr-abl, composição farmacêutica, e, kit
EP2231156A1 (en) 2007-12-07 2010-09-29 Fibrogen, Inc. Methods for increasing white blood cells
BRPI1013988A2 (pt) * 2009-04-06 2016-04-05 Daiichi Sankyo Co Ltd composto, composição farmacêutica , e, uso de um composto ou um sal farmacologicamente aceitável do mesmo
AU2010239188B2 (en) 2009-04-22 2016-03-31 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
EP2588455B1 (en) * 2010-07-02 2018-04-04 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
KR20130140020A (ko) * 2010-10-22 2013-12-23 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 억제제로서의 아미노-피롤리딘-아제티딘 다이아미드
CA2743391A1 (en) 2011-05-27 2012-11-27 Queen's University At Kingston Compounds and methods for catalytic directed ortho substitution of aromatic amides and esters
US9278960B2 (en) 2011-11-03 2016-03-08 Merck Sharp & Dohme Corp. Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use
WO2013086229A1 (en) 2011-12-07 2013-06-13 Amgen Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
US20150157584A1 (en) 2012-06-11 2015-06-11 The J. David Gladstone Institutes Inhibitors of hippo-yap signaling pathway
SG11201500234YA (en) 2012-07-16 2015-02-27 Fibrogen Inc Process for making isoquinoline compounds
JP6113354B2 (ja) * 2013-05-03 2017-04-12 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 神経新生刺激イソキノリン誘導体
US20140336182A1 (en) 2013-05-13 2014-11-13 Amgen Inc. Aurora Kinase Modulators and Method of Use
US9212182B2 (en) 2013-06-12 2015-12-15 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
MX2016010056A (es) 2014-02-06 2016-11-15 Abbvie Inc 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso.
JP6377245B2 (ja) 2014-03-24 2018-08-22 グアンドン ジョンシェン ファーマシューティカル カンパニー リミテッド Smo阻害剤としてのキノリン誘導体
EP3247705B1 (en) 2015-01-20 2019-11-20 Millennium Pharmaceuticals, Inc. Quinazoline and quinoline compounds and uses thereof as nampt inhibitors
EP3156404A1 (en) 2015-10-15 2017-04-19 Inventiva New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma
EP3868750A1 (en) 2015-11-20 2021-08-25 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
WO2018028591A1 (zh) 2016-08-09 2018-02-15 殷建明 一种喹啉衍生物及其用途
WO2019040389A1 (en) 2017-08-21 2019-02-28 Palmese Giuseppe R RENEWABLE FURANE AMINE CURING AGENTS FOR THERMOSETTING EPOXY PLASTIC
HRP20251184T1 (hr) 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
CN112236172A (zh) * 2018-01-30 2021-01-15 福宏治疗公司 用于治疗病症的方法和化合物
EP3877356A4 (en) 2018-11-09 2022-06-22 Vivace Therapeutics, Inc. BICYCLIC LINKS
AU2020257207B2 (en) 2019-04-16 2026-06-04 Vivace Therapeutics, Inc. Bicyclic compounds
US20240025913A1 (en) 2020-10-21 2024-01-25 Vivace Therapeutics, Inc. Tertiary carboxamide compounds

Similar Documents

Publication Publication Date Title
JP7653362B2 (ja) 二環式化合物
JP2020533280A5 (cg-RX-API-DMAC7.html)
ES2791315T3 (es) Agonistas triazoles del receptor APJ
JP2018515581A5 (cg-RX-API-DMAC7.html)
JP2020518669A5 (cg-RX-API-DMAC7.html)
RU2491286C1 (ru) Полиморфная форма соединения 2-аминотиазола в качестве ингибитора киназы и способ ее получения
JP2022529700A5 (cg-RX-API-DMAC7.html)
JP2022529642A5 (cg-RX-API-DMAC7.html)
JP2021519783A5 (cg-RX-API-DMAC7.html)
ES2911040T3 (es) Nuevos derivados de heteroaril amida como inhibidores selectivos de histona deacetilasa 1 y 2 (HDAC1/2)
ES2908938T3 (es) Nuevos derivados de benzamida como moduladores de PPAR-gamma
US7951957B2 (en) Substituted benzimidazoles and their use for inducing apoptosis
JP2019514883A5 (cg-RX-API-DMAC7.html)
CA2885969A1 (en) Substitued pyridine derivatives and compositions thereof useful as inhibitors of histone demethylases
AU2004268621A1 (en) c-Kit modulators and methods of use
PT1089998E (pt) Derivados de epotilona e sua síntese e utilização
EA026892B1 (ru) ТРИАЗОЛОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ mPGES-1
JP2008520742A5 (cg-RX-API-DMAC7.html)
JP2005505595A5 (cg-RX-API-DMAC7.html)
JP2021523168A5 (cg-RX-API-DMAC7.html)
ES2300775T3 (es) Furazanobencimidazoles.
ES2338060T3 (es) Componentes de tipo ariloxi y ariltoxia-cetofenona para el tratamiento del cancer.
EP3303290A1 (en) Ror gamma (rory) modulators
JP2018515491A5 (cg-RX-API-DMAC7.html)
AU2015218775C1 (en) Antimitotic amides for the treatment of cancer and proliferative disorders